What Works For Anxiety Disorders-Anti-Anxiety Drugs

Anafranil™

(Clomipramine hydrochloride) Capsules USP (25 mg, 50 mg, and 75 mg) Rx only

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Clomipramine hydrochloride is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) (see WARNINGS, Clinical Worsening and Suicide Risk; PRECAUTIONS, Information for Patients; and PRECAUTIONS, Pediatric Use).

DESCRIPTION

Anafranil™ (clomipramine hydrochloride) Capsules USP is an antiobsessional drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. Anafranil is available as capsules of 25, 50, and 75 mg for oral administration.

Medication Guide – Anafranil™ (clomipramine hydrochloride) Capsules USP

Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions

Read the Medication Guide that comes with you or your family member’s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider about:

• all risks and benefits of treatment with antidepressant medicines
• all treatment choices for depression or other serious mental illness

What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?

1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.
2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.
3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

• Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
• Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
• Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:

• thoughts about suicide or dying
• attempts to commit suicide
• new or worse depression
• new or worse anxiety
• feeling very agitated or restless
• panic attacks
• trouble sleeping (insomnia)
• new or worse irritability
• acting aggressive, being angry, or violent
• acting on dangerous impulses
• an extreme increase in activity and talking (mania)
• other unusual changes in behavior or mood

Visual problems

• eye pain
• changes in vision
• swelling or redness in or around the eye

Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.

Who should not take Anafranil?

Do not take Anafranil if you:

• take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.

o Do not take an MAOI within 2 weeks of stopping Anafranil unless directed to do so by your physician.

o Do not start Anafranil if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician.

What else do I need to know about antidepressant medicines?

• Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.
• Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.
• Antidepressant medicines have other side effects. Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.
• Antidepressant medicines can interact with other medicines. Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.
• Not all antidepressant medicines prescribed for children are FDA approved for use in children. Talk to your child’s healthcare provider for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Mallinckrodt, the “M” brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.

© 2014 Mallinckrodt.

Manufactured by

Patheon Inc.

Whitby, Ontario, Canada

L1N 5Z5

for Mallinckrodt Inc.

Hazelwood, MO 63042 USA

Rev 06/2014

Related articles across the web

• Here’s what it’s really like to have obsessive-compulsive disorder
• What Does the FDA Have to Say About Supplements?
• Seven months.
• Protocol for a Diaper Change or Open Heart Surgery?
• Morning Roundup: Urban Meyer on dealing with mental illness | Apple Maps adds COTA | Homestead Beer honored | Pawpaws and beer

A previous article entitled APLENZIN-(bupropion hydrobromide) provides information... Abnormal thoughts, abuse prescription medicines ve Aggressive

Related posts

• WELLBUTRIN® Tablets (WELL byu-trin)- (bupropion hydrochloride) (0)
• APLENZIN-(bupropion hydrobromide) (0)
• TRINTELLIX [trin’-tel-ix] (vortioxetine) (0)
• PRISTIQ® (pris-TEEK) (desvenlafaxine) (0)
• FORFIVO XL® (0)
• OleptroTM (Oh-LEP-troe) (0)
• FETZIMA® (fet-ZEE-muh) (levomilnacipran) (0)
• SEROQUEL (quetiapine fumarate) Tablets – Medication Guide (0)
• Sabril®- Vigabatrin (0)
• PEXEVA® (pex-EE-va) (paroxetine mesylate) (0)

Tags: acting aggressive, all risks and benefits of treatment with antidepressant medicines, all treatment choices for depression, Anafranil, antibiotic linezolid, Antidepressant Drugs, Antidepressant medicines, antiobsessional drug, attempts to commit suicide, behaviors, being angry, Changes in vision, clomipramine hydrochloride, depression, dibenzazepine, Eye pain, feeling very agitated or restless, feelings, insomnia, major depressive disorder, mania, MAOI, MDD, monoamine oxidase inhibitor, mood, new or worse anxiety, new or worse depression, new or worse irritability, obsessive-compulsive disorder, OCD, panic attacks, serious mental illnesses, suicidal thoughts, Suicidality, thoughts, thoughts about suicide or dying, Tricyclic antidepressants